Schonfeld Strategic Advisors LLC Bio Line Rx Ltd. Transaction History

Schonfeld Strategic Advisors LLC

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 Nov 14, 2022	SELL	$0.88 - $1.91 $176 - $382	-200 Reduced 1.39%	14,200 $13,000
Q2 2022 Aug 15, 2022	SELL	$1.06 - $1.82 $212 - $364	-200 Reduced 1.37%	14,400 $19,000
Q1 2022 May 16, 2022	BUY	$1.46 - $2.18 $2,628 - $3,924	1,800 Added 14.06%	14,600 $24,000
Q4 2021 Feb 14, 2022	BUY	$1.98 - $3.06 $1,386 - $2,142	700 Added 5.79%	12,800 $26,000
Q3 2021 Nov 16, 2021	BUY	$2.65 - $3.35 $32,065 - $40,535	12,100 New	12,100 $33,000
Q2 2021 Aug 16, 2021	SELL	$2.63 - $4.88 $201,195 - $373,320	-76,500 Closed	0 $0
Q1 2021 May 17, 2021	BUY	$2.38 - $4.0 $97,580 - $164,000	41,000 Added 115.49%	76,500 $213,000
Q4 2020 Feb 16, 2021	BUY	$1.47 - $3.62 $52,185 - $128,510	35,500 New	35,500 $90,000

3.3M

46.5K

6.3K

Ticker BLRX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 61,524,500
Market Cap $29.5M
Description
BioLineRx Ltd., a clinical-stage biopharmaceutical development company, focuses on oncology. The company develops Motixafortide, a peptide, which has completed Phase 3 clinical trials for the treatment of autologous stem cell mobilization and Phase 2a clinical trials for the treatment of pancreatic cancer; and that is in Phase 2 clinical trials ...

Get notified when there are updates to the investment portfolio of Schonfeld Strategic Advisors LLC, based on Form 13F filings with the SEC.

Stay updated on Schonfeld Strategic Advisors LLC with notifications on news.